Eli Lilly Grants Expanded Access to Innovative Weight Loss Drug, Retatrutide
In a significant development in the realm of weight management and wellness, Eli Lilly announced on August 3, 2026, that it would broaden the patient group eligible for early access to retatrutide—its potent investigational obesity drug—prior to receiving U.S. FDA approval.
This announcement followed reports by STAT News that several physicians seeking expanded access for their patients had not received any feedback from the pharmaceutical company. Lilly has since confirmed the establishment of a formal expanded access program and is currently reviewing requests from healthcare providers.
Eligibility for the program requires patients to be 18 years or older, have refractory obesity despite tolerating the highest approved dose of obesity therapy, and suffer from at least two serious or life-threatening obesity-related complications. It is important to note that patients cannot apply directly; a treating doctor must initiate the request.
Retatrutide is a cutting-edge triple hormone receptor agonist that simultaneously targets the GLP-1, GIP, and glucagon pathways. This goes beyond existing drugs like Lilly’s own Zepbound (dual-target) and Novo Nordisk’s Wegovy (single-target). Late-stage trials revealed that participants on the highest 12 mg dose lost an average of 28.3% of their body weight over an 80-week period. Lilly plans to file for FDA approval in the first quarter of 2027.
This development marks a pivotal moment in obesity treatment and is expected to revolutionize the approach physicians and patients take towards weight management wellness in the near future.
Source: Quartz – Eli Lilly Expanding Early Access to Retatrutide Weight Loss Drug (August 4, 2026)